Ga-68 labeled Baicalein: Potential Dual (Optical & Radio) Tracer for Lung Cancer Imaging
Project no. 22485 · Status: Kapanmış (Yayın bekleniyor) · 2021
Summary
<p>One of the major challenges in cancer diagnosis and treatment is the issue of the specificity of radiopharmaceuticals to the target region. The fact that lung cancer (LC) ranks first among cancer-related deaths, the vital importance of early diagnosis, and the use of non-specific PET images obtained with 18F-FDG, which typically uses the glucose mechanism for clinical diagnosis, makes it crucial to develop new imaging agents with high specificity for lung cancer. The plant-derived flavonoid Baicalein, which will be used as the starting material in this project, has been shown to have therapeutic potential against lung cancer in various in vitro/in vivo studies in the literature.</p><p>Each of the non-invasive imaging techniques used in clinics (CT, MRI, SPECT, PET, optical imaging, and ultrasound) has its own advantages and disadvantages, based on anatomical, functional, and resolution parameters. With the development of multi-labeled imaging agents, the target region can be evaluated using two or more different imaging techniques in a multi-modality approach. This allows for the combination of the strengths and advantages of each method. Therefore, developing multi-functional imaging agents that can be detected using multiple imaging techniques simultaneously would be advantageous. In our project, the detection of the newly synthesized potential imaging agent using two different modalities will increase diagnostic reliability.</p><p>In our project, the synthesis of Gallium-68/inactive Gallium (68/natGa) and fluorescent (IRDye 800CW) labeled Baicalein (BA) is aimed, and the potential of the synthesized product in dual modality (PET/Optical) imaging for lung cancer (LC) is demonstrated.</p><p>The potential of the synthesized flavonoid targeting the LC pathways with 68/natGa and fluorescent labeling in the project was evaluated in vitro on healthy (BEAS-2B) and cancer (A549) lung cells, and in vivo methods on nude mice with a xenograft tumor model. Imaging studies were performed using PET/CT and Optical (IVIS) systems on the tumor model.</p>